Opinion|Videos|January 13, 2025
ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant
Panelists discuss how the AURIGA trial demonstrates superior outcomes with daratumumab plus lenalidomide maintenance compared with lenalidomide alone after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma while examining key subgroup analyses that inform treatment decisions regarding posttransplant maintenance therapy selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For patients who have received ASCT, please comment on the latest data from the AURIGA trial, evaluating daratumumab plus lenalidomide maintenance in NDMM.
- AURIGA trial, subgroup analysis
- How does the data impact your choice of subsequent treatment, post induction therapy?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5